View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 17, 2021

GSK/CureVac’s second-gen mRNA Covid-19 vaccine boosts immune response in preclinical study

The companies plan to launch the first clinical trial of the CV2CoV vaccine in the fourth quarter of this year.

GlaxoSmithKline (GSK) and CureVac have reported that their second-generation vaccine candidate, CV2CoV, provided robust immune responses against SARS-CoV-2 challenge in a preclinical study in non-human primates.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The vaccine candidate is a non-chemically modified messenger ribonucleic acid (mRNA) that encodes the prefusion stabilised full-length spike protein of SARS-CoV-2. It is formulated within lipid nanoparticles.

In the preclinical trial, cynomolgus macaques were inoculated with two 12µg doses of either CureVac’s first-generation vaccine candidate, CVnCoV, or CV2CoV at a gap of 28 days.

Findings showed that CV2CoV could better stimulate innate and adaptive immune responses, offering quick onset of response, increased antibody titers and robust activation of memory B and T cells versus CVnCoV.

The study also analysed the effect of variants of concern and variants of interest such as Alpha, Beta, Delta, Kappa and the Lambda variant on neutralising antibody titers.

Increased antibody neutralising ability was reported with CV2CoV across all studied variants.

Animals receiving CV2CoV were observed to be well-protected following challenge infection using the original virus, with highly efficient viral clearance in the lungs and nasal passages.

GSK noted that preclinical studies in various animal models indicate the ability of the CV2CoV vaccine to stimulate quicker and robust immune responses.

CureVac chief scientific officer Dr Igor Splawski said: “In this animal model, CV2CoV is shown to induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with SARS-CoV-2.

“The current study shows that the immune responses and resulting protection produced by our second-generation candidate, based on our mRNA technology featuring targeted optimisations, are substantially improved in non-human primates against both the original SARS-CoV-2 virus as well as the Beta and Delta Variants of Concern and the Lambda Variant of Interest.”

The first clinical trial of the CV2CoV vaccine is anticipated to commence in the fourth quarter of this year.

CureVac and GSK initially partnered in July last year to develop novel products using the former’s second-generation RNA technology for various infectious disease targets.

The collaboration was further extended in February this year to develop next-generation mRNA Covid-19 vaccines.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU